They are currently recruiting for volunteer subjects in Washington, DC (George Washington U) and San Antonio, TX (U of Texas Health Science Center), with additional sites not yet recruiting in Atlanta, GA and Seattle, WA. Contact info for the researchers is at the bottom of the clinicaltrials.gov page for the trial:
[think before following links] [think before following links] https://clinicaltrials.gov/ct2/show/NCT05001373
This is only a Phase I study, and the target number of participants is small (56). The primary goal is to demonstrate safety, and the secondary goal is to evaluate immunogenicity (whether the vaccine produces an immune response). It is open to people of either biological sex, ages 18-50. They are not accepting (for Phase I) people who test positive for HIV and people who are at risk for HIV exposure (this makes sense - they need to make sure that any health results observed and any antibodies generated are from the vaccine and not from the virus).